Eli Lilly And Co (NYSE:LLY) is scheduled to report its quarterly results on Thursday.
The company is likely to report its first-quarter results in line with peers, with some tariff and policy-related commentary during the earnings call, according to Goldman Sachs.
The Eli Lilly Analyst: Analyst Asad Haider maintained a Buy rating and price target of $888.
The Eli Lilly Thesis: “We expect a decent showing from the tirizepatide franchise (Mounjaro/Zepbound) following the uneven performance featuring misses in the last two quarters,” Haider wrote in the note.
Check out other analyst stock ratings.
Investors are likely to focus on Eli Lilly’s obesity franchise, where the company has “continued to solidify its leadership position and frontrunner status in both the GLP-1 injectible market,” he added.
Investor focus should also be on the oral obesity pill market, “on the heels of the recent positive ACHIEVE-1 readout for orforglipron int T2D patients,” the analyst stated.
The ATTAIN-1 trial is expected in the third quarter and will be “orforglipron’s first readout in obesity and hence represents a significant event in the oral obesity space,” he wrote.
LLY Price Action: Shares of Eli Lilly had risen by 1.61% to $891.25 at the time of publication on Tuesday.
Read More:
• Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
Photo: Shutterstock
